Ipx-822 |work| May 2026

The core objective of INI-822 is to inhibit specific pathways involved in the progression of liver fibrosis and inflammation. Unlike broad-spectrum anti-inflammatories, this compound targets the underlying metabolic dysregulation that leads to fat accumulation and subsequent scarring of liver tissue.

There is no widely recognized drug with the exact code "IPX-822." However, it is frequently confused with , a leading investigational small molecule developed by Inipharm . IPX-822